But, multiple patient deaths in the triplet group sparked safety fears
Xia B, Yang M, Nguyen LH, He Q, Zhen J, Yu Y, et al
Vulvovaginal dryness/infection terms were not retrieved as prominent terms in the accessible text searches of that paper

These studies assessed the efficacy and safety of escalating weekly doses of tirzepatide from 5 mg to 15 mg over 12 weeks compared to placebo,188 and over 26 weeks compared to placebo or dulaglutide, selective GLP-1RAs.189 Subsequently, tirzepatide has been extensively investigated in the SURPASS program, a comprehensive development initiative targeting T2DM that is inadequately controlled by various glucose-lowering regimens, including lifestyle alone (SURPASS-1),190 metformin monotherapy (SURPASS-2),191 metformin with or without sodium-glucose co-transporter 2 inhibitors (SGLT2i) (SURPASS-3),192 combination therapy including metformin, SGLT2i, and sulfonylureas (SURPASS-4),193 insulin glargine with or without metformin (SURPASS-5),88 and insulin lispro with basal insulin (SURPASS-6).194 Across all SURPASS trials, tirzepatide demonstrated a dose-dependent reduction in HbA1c levels, which consistently exceeded the reductions observed with comparator treatments

Clinical trials demonstrate that semaglutide monotherapy produces meaningful weight reductions, improved glycemic control, and cardiovascular benefits in patients with obesity and related conditions